Concord Biotech Limited’s Board of Directors met on October 27, 2026, to approve the unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The board also fixed November 4, 2026, as the record date for a proposed bonus equity share issuance, subject to shareholder approval. Additionally, the board reconstituted key committees, including the Audit Committee and Nomination and Remuneration Committee.
Financial Performance Approved
Concord Biotech Limited announced that its Board of Directors, following a review and recommendation from the Audit Committee, has approved the unaudited standalone and consolidated financial results for the second quarter and half-year period ending September 30, 2026. These results, along with the limited review reports from statutory auditors BSR & Co. LLP, were submitted to the stock exchanges.
Bonus Share Issuance Record Date Set
Further to a previous intimation on September 23, 2026, the Board has officially designated Wednesday, November 4, 2026, as the record date. This date will be used to identify shareholders eligible for the allotment of bonus equity shares. The company will issue a separate disclosure to the stock exchanges regarding this matter.
Committee Reconstitution
In compliance with regulatory provisions, the Board of Directors has also reconstituted several key committees. These include the Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee. The revised composition of these committees has been provided as Annexure A to the filing.
Meeting Details
The Board meeting commenced at 3:30 PM and concluded at 4:45 PM on October 27, 2026.
Source: BSE
